Clinical Trial

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

Study acronym: RESOLVE-AMI
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-17; most recent amendment 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-06-26
Trial Details
NCT Number NCT06515730
Lead Sponsor Karolinska Institutet
Collaborators: Karolinska Trial Alliance, Swedish Heart Lung Foundation, The Swedish Research Council, Stockholm County Council ALF/PPG
Conditions Left Ventricular Thrombus, Acute Myocardial Infarction
Enrollment 212 participants
Start Date 2025-04-08
Primary Completion 2028-04-08 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-01